Company intelligence / Profile preview

Codoon

Ownership: Private
Development stage: Other

Overview

Codone Biotechnology has established proprietary platforms for developing suppressor-tRNA therapies delivered via AAV vectors to treat severe diseases caused by premature stop codons. The company collaborates with leading academic institutions and has a scientific advisory board with expertise in RNA processing, protein translation, gene therapy, and rare disease clinical development. No clinical results have been published as of June 2025.

Therapeutic areas: Rare Diseases
Modalities: RNA therapyGene therapy (specifically suppressor-tRNA and AAV delivery)
Industry: Biotech

Partnerships

University of Massachusetts research collaboration agreement signed December 2022

Beyond the preview

Go deeper on Codoon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Codoon.

Explore the full profile